BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
Dynogen developed a portfolio of therapies for gastrointestinal and genitourinary disorders. It went out of business in 2009.
Dynogen Pharmaceuticals
Waltham, MA
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.